,162 MDM2 inhibitors can potentiate the activity of transporter associated with antigen processing 1 and endoplasmic reticulum aminopeptidase 1 through a p53-dependent pathway, which ultimately leads to an increase in MHC-I expression in tumor cells,163 triggering a subsequent T-cell anti-tumor response. This evidence concerns the gene TP53 and neoplasm.